Đọc thêm Raloxifene

Barrett-Connor E (2001). “Raloxifene: risks and benefits”. Ann N Y Acad Sci. 949: 295–303. doi:10.1111/j.1749-6632.2001.tb04036.x. PMID 11795366.
Heringa M (2003). “Review on raloxifene: profile of a selective estrogen receptor modulator”. Int J Clin Pharmacol Ther. 41 (8): 331–45. PMID 12940590.
Sporn MB, Dowsett SA, Mershon J, Bryant HU (2004). “Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action”. Clin Ther. 26 (6): 830–40. doi:10.1016/s0149-2918(04)90127-0. PMID 15262454.
Vogel VG (2009). “The NSABP Study of Tamoxifen and Raloxifene (STAR) trial”. Expert Rev Anticancer Ther. 9 (1): 51–60. doi:10.1586/14737140.9.1.51. PMC 2785111. PMID 19105706.
Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N (2009). “The use of tamoxifen and raloxifene for the prevention of breast cancer”. Recent Results Cancer Res. 181: 113–9. PMC 5110043. PMID 19213563.
Vogel VG (2011). “Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women”. Breast Cancer (Dove Med Press). 3: 127–37. doi:10.2147/BCTT.S11288. PMC 3846694. PMID 24367182.
Yang ZD, Yu J, Zhang Q (2013). “Effects of raloxifene on cognition, mental health, sleep and sexual function in menopausal women: a systematic review of randomized controlled trials”. Maturitas. 75 (4): 341–8. doi:10.1016/j.maturitas.2013.05.010. PMID 23764354.

Tài liệu tham khảo